Premium
P2–424: Predictors of response to galantamine in subjects with Alzheimer's disease
Author(s) -
Woodward Michael,
Boundy Karyn,
Brodaty Henry
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1265
Subject(s) - galantamine , logistic regression , univariate , spouse , medicine , univariate analysis , disease , alzheimer's disease , psychology , dementia , donepezil , multivariate analysis , statistics , multivariate statistics , mathematics , sociology , anthropology
tre, randomised, placebo-controlled, parallel group, double-blind studies were included in this analysis; one study involved patients on stabilised donepezil. These studies included 506 patients on memantine and 499 on placebo. Further supportive evidence comes from a 12-week study of dementia in a nursing home setting (AD patients: N 41 on memantine, 38 on placebo). Functional symptoms were evaluated using the ADCS-ADL19 scale in the three studies and G2 scale (D-test) in the nursing-home study. Statistical analyses were performed using ANCOVA on ADCS-ADL19 total scores; single items were analysed using non-parametric methods with OC and LOCF approaches. Results: ADCS-ADL19 total scores showed a statistically significant benefit (p 0.0001) of memantine vs. placebo (OC). Single items showing statistical significance in favour of memantine were: toileting, grooming, watching TV, making conversation, and finding belongings (p 0.05). In the nursing home population, G2 scale items significantly improved with memantine were: ability to stand up, move, drink, eat, dress, and use the toilet. Conclusion: These results show that memantine treatment improves functional abilities in patients with moderate to severe AD. Memantine’s significant and consistent benefits on basic ADLs and complex activities allow patients to retain greater independence and dignity.